# Abbott Laboratories quarterly revenue

entity: /record/abbott-laboratories.md  
predicate: quarterly_revenue  
page: /record/abbott-laboratories/quarterly_revenue  
as_of: 2026-11-09  
cite: AsOf. "Abbott Laboratories quarterly revenue: 13,013,000,000 United States dollar", as of 2026-09-30. Claim clm_080974839279, https://asof.is/claim/clm_080974839279, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026070154/0001628280-26-070154-index.htm.  

As of November 9, 2026, Abbott Laboratories's quarterly revenue on the AsOf record is $13.01 billion, dated September 30, 2026, from a primary source (sec.gov).

56 claims on Abbott Laboratories's quarterly revenue, 1 open and 55 superseded, each dated and sourced; a replaced value is closed with an end date, never deleted.

## Current quarterly revenue

What the record asserts on 2026-11-09.

- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 13,013,000,000 United States dollar | valid 2026-09-30 to present | conf 0.95 | valid | [clm_080974839279](/claim/clm_080974839279.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000162828026070154/0001628280-26-070154-index.htm

## Every dated value

One claim per line, oldest first. Superseded claims stay visible.

- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 7,314,021,000 United States dollar | valid 2008-06-30 to 2008-09-30 | conf 0.95 | superseded | superseded_by [clm_79675DAFEFFB](/claim/clm_79675DAFEFFB.md) | [clm_53BF00022ED3](/claim/clm_53BF00022ED3.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000110465909048013/0001104659-09-048013-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 7,497,660,000 United States dollar | valid 2008-09-30 to 2009-03-31 | conf 0.95 | superseded | superseded_by [clm_6D1B34C8DAA9](/claim/clm_6D1B34C8DAA9.md) | [clm_79675DAFEFFB](/claim/clm_79675DAFEFFB.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000110465909063192/0001104659-09-063192-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 6,718,368,000 United States dollar | valid 2009-03-31 to 2009-06-30 | conf 0.95 | superseded | superseded_by [clm_3BEDCDE314E8](/claim/clm_3BEDCDE314E8.md) | [clm_6D1B34C8DAA9](/claim/clm_6D1B34C8DAA9.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000110465910033097/0001104659-10-033097-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 7,494,876,000 United States dollar | valid 2009-06-30 to 2009-09-30 | conf 0.95 | superseded | superseded_by [clm_F40C461D1F9A](/claim/clm_F40C461D1F9A.md) | [clm_3BEDCDE314E8](/claim/clm_3BEDCDE314E8.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000110465909048013/0001104659-09-048013-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 7,761,336,000 United States dollar | valid 2009-09-30 to 2010-03-31 | conf 0.95 | superseded | superseded_by [clm_882692ECC7C2](/claim/clm_882692ECC7C2.md) | [clm_F40C461D1F9A](/claim/clm_F40C461D1F9A.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000110465909063192/0001104659-09-063192-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 7,698,354,000 United States dollar | valid 2010-03-31 to 2010-06-30 | conf 0.95 | superseded | superseded_by [clm_BC7C9A4BD8E1](/claim/clm_BC7C9A4BD8E1.md) | [clm_882692ECC7C2](/claim/clm_882692ECC7C2.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000110465910033097/0001104659-10-033097-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 8,826,014,000 United States dollar | valid 2010-06-30 to 2010-09-30 | conf 0.95 | superseded | superseded_by [clm_A55F00358DA8](/claim/clm_A55F00358DA8.md) | [clm_BC7C9A4BD8E1](/claim/clm_BC7C9A4BD8E1.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000110465910042282/0001104659-10-042282-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 8,674,505,000 United States dollar | valid 2010-09-30 to 2011-03-31 | conf 0.95 | superseded | superseded_by [clm_E6DA945AC1D9](/claim/clm_E6DA945AC1D9.md) | [clm_A55F00358DA8](/claim/clm_A55F00358DA8.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000110465910056473/0001104659-10-056473-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 9,040,850,000 United States dollar | valid 2011-03-31 to 2011-06-30 | conf 0.95 | superseded | superseded_by [clm_2BC0D1181F4B](/claim/clm_2BC0D1181F4B.md) | [clm_E6DA945AC1D9](/claim/clm_E6DA945AC1D9.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000110465911026773/0001104659-11-026773-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 9,616,291,000 United States dollar | valid 2011-06-30 to 2011-09-30 | conf 0.95 | superseded | superseded_by [clm_60A7CF8613BF](/claim/clm_60A7CF8613BF.md) | [clm_2BC0D1181F4B](/claim/clm_2BC0D1181F4B.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000110465911043664/0001104659-11-043664-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 9,816,665,000 United States dollar | valid 2011-09-30 to 2012-03-31 | conf 0.95 | superseded | superseded_by [clm_D9ABEC05FB6F](/claim/clm_D9ABEC05FB6F.md) | [clm_60A7CF8613BF](/claim/clm_60A7CF8613BF.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000110465911061064/0001104659-11-061064-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 9,456,633,000 United States dollar | valid 2012-03-31 to 2012-06-30 | conf 0.95 | superseded | superseded_by [clm_4F0F9A9FCDF2](/claim/clm_4F0F9A9FCDF2.md) | [clm_D9ABEC05FB6F](/claim/clm_D9ABEC05FB6F.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000110465912034444/0001104659-12-034444-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 9,807,100,000 United States dollar | valid 2012-06-30 to 2012-09-30 | conf 0.95 | superseded | superseded_by [clm_B817BB7C1C39](/claim/clm_B817BB7C1C39.md) | [clm_4F0F9A9FCDF2](/claim/clm_4F0F9A9FCDF2.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000110465912055154/0001104659-12-055154-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 9,773,241,000 United States dollar | valid 2012-09-30 to 2013-03-31 | conf 0.95 | superseded | superseded_by [clm_83226985F7C5](/claim/clm_83226985F7C5.md) | [clm_B817BB7C1C39](/claim/clm_B817BB7C1C39.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000110465912075249/0001104659-12-075249-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 5,377,895,000 United States dollar | valid 2013-03-31 to 2013-06-30 | conf 0.95 | superseded | superseded_by [clm_A00248C0A983](/claim/clm_A00248C0A983.md) | [clm_83226985F7C5](/claim/clm_83226985F7C5.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000110465913038811/0001104659-13-038811-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 5,446,025,000 United States dollar | valid 2013-06-30 to 2013-09-30 | conf 0.95 | superseded | superseded_by [clm_05BD8CC8CEE0](/claim/clm_05BD8CC8CEE0.md) | [clm_A00248C0A983](/claim/clm_A00248C0A983.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000110465913060300/0001104659-13-060300-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 5,369,138,000 United States dollar | valid 2013-09-30 to 2014-03-31 | conf 0.95 | superseded | superseded_by [clm_B233A6055639](/claim/clm_B233A6055639.md) | [clm_05BD8CC8CEE0](/claim/clm_05BD8CC8CEE0.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000110465913082270/0001104659-13-082270-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 5,244,000,000 United States dollar | valid 2014-03-31 to 2014-06-30 | conf 0.95 | superseded | superseded_by [clm_FD8317313DF1](/claim/clm_FD8317313DF1.md) | [clm_B233A6055639](/claim/clm_B233A6055639.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000110465914035832/0001104659-14-035832-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 5,551,000,000 United States dollar | valid 2014-06-30 to 2014-09-30 | conf 0.95 | superseded | superseded_by [clm_82A6A707FD7C](/claim/clm_82A6A707FD7C.md) | [clm_FD8317313DF1](/claim/clm_FD8317313DF1.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000110465914056950/0001104659-14-056950-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 5,104,000,000 United States dollar | valid 2014-09-30 to 2015-03-31 | conf 0.95 | superseded | superseded_by [clm_217D209218A4](/claim/clm_217D209218A4.md) | [clm_82A6A707FD7C](/claim/clm_82A6A707FD7C.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000110465914077769/0001104659-14-077769-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 4,897,000,000 United States dollar | valid 2015-03-31 to 2015-06-30 | conf 0.95 | superseded | superseded_by [clm_1E113FF89F7B](/claim/clm_1E113FF89F7B.md) | [clm_217D209218A4](/claim/clm_217D209218A4.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000110465915034919/0001104659-15-034919-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 5,170,000,000 United States dollar | valid 2015-06-30 to 2015-09-30 | conf 0.95 | superseded | superseded_by [clm_4DDA3D71417E](/claim/clm_4DDA3D71417E.md) | [clm_1E113FF89F7B](/claim/clm_1E113FF89F7B.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000110465915055905/0001104659-15-055905-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 5,150,000,000 United States dollar | valid 2015-09-30 to 2016-03-31 | conf 0.95 | superseded | superseded_by [clm_33CB344232AF](/claim/clm_33CB344232AF.md) | [clm_4DDA3D71417E](/claim/clm_4DDA3D71417E.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000110465915076189/0001104659-15-076189-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 4,885,000,000 United States dollar | valid 2016-03-31 to 2016-06-30 | conf 0.95 | superseded | superseded_by [clm_1B83117F5484](/claim/clm_1B83117F5484.md) | [clm_33CB344232AF](/claim/clm_33CB344232AF.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000110465916117710/0001104659-16-117710-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 5,333,000,000 United States dollar | valid 2016-06-30 to 2016-09-30 | conf 0.95 | superseded | superseded_by [clm_8064646C7C6E](/claim/clm_8064646C7C6E.md) | [clm_1B83117F5484](/claim/clm_1B83117F5484.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000110465916136572/0001104659-16-136572-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 5,302,000,000 United States dollar | valid 2016-09-30 to 2017-03-31 | conf 0.95 | superseded | superseded_by [clm_15BAEA02B893](/claim/clm_15BAEA02B893.md) | [clm_8064646C7C6E](/claim/clm_8064646C7C6E.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000110465916154583/0001104659-16-154583-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 6,335,000,000 United States dollar | valid 2017-03-31 to 2017-06-30 | conf 0.95 | superseded | superseded_by [clm_29C8A48CFFA6](/claim/clm_29C8A48CFFA6.md) | [clm_15BAEA02B893](/claim/clm_15BAEA02B893.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000110465918029831/0001104659-18-029831-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 6,637,000,000 United States dollar | valid 2017-06-30 to 2017-09-30 | conf 0.95 | superseded | superseded_by [clm_402A58FFA584](/claim/clm_402A58FFA584.md) | [clm_29C8A48CFFA6](/claim/clm_29C8A48CFFA6.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000110465918048736/0001104659-18-048736-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 6,829,000,000 United States dollar | valid 2017-09-30 to 2018-03-31 | conf 0.95 | superseded | superseded_by [clm_C3C0F612B29F](/claim/clm_C3C0F612B29F.md) | [clm_402A58FFA584](/claim/clm_402A58FFA584.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000110465918065076/0001104659-18-065076-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 7,390,000,000 United States dollar | valid 2018-03-31 to 2018-06-30 | conf 0.95 | superseded | superseded_by [clm_79374FAAB118](/claim/clm_79374FAAB118.md) | [clm_C3C0F612B29F](/claim/clm_C3C0F612B29F.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000110465918029831/0001104659-18-029831-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 7,767,000,000 United States dollar | valid 2018-06-30 to 2018-09-30 | conf 0.95 | superseded | superseded_by [clm_DE1BAF682D4F](/claim/clm_DE1BAF682D4F.md) | [clm_79374FAAB118](/claim/clm_79374FAAB118.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000110465918048736/0001104659-18-048736-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 7,656,000,000 United States dollar | valid 2018-09-30 to 2019-03-31 | conf 0.95 | superseded | superseded_by [clm_C0322CACEF5F](/claim/clm_C0322CACEF5F.md) | [clm_DE1BAF682D4F](/claim/clm_DE1BAF682D4F.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000110465918065076/0001104659-18-065076-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 7,535,000,000 United States dollar | valid 2019-03-31 to 2019-06-30 | conf 0.95 | superseded | superseded_by [clm_BDDE4A079F3F](/claim/clm_BDDE4A079F3F.md) | [clm_C0322CACEF5F](/claim/clm_C0322CACEF5F.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000110465919026018/0001104659-19-026018-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 7,979,000,000 United States dollar | valid 2019-06-30 to 2019-09-30 | conf 0.95 | superseded | superseded_by [clm_6EA4DA762D97](/claim/clm_6EA4DA762D97.md) | [clm_BDDE4A079F3F](/claim/clm_BDDE4A079F3F.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000141057819000606/0001410578-19-000606-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 8,076,000,000 United States dollar | valid 2019-09-30 to 2020-03-31 | conf 0.95 | superseded | superseded_by [clm_0C0541A5EB25](/claim/clm_0C0541A5EB25.md) | [clm_6EA4DA762D97](/claim/clm_6EA4DA762D97.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000110465919058323/0001104659-19-058323-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 7,726,000,000 United States dollar | valid 2020-03-31 to 2020-06-30 | conf 0.95 | superseded | superseded_by [clm_9EA536FA1B5B](/claim/clm_9EA536FA1B5B.md) | [clm_0C0541A5EB25](/claim/clm_0C0541A5EB25.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000110465920053384/0001104659-20-053384-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 7,328,000,000 United States dollar | valid 2020-06-30 to 2020-09-30 | conf 0.95 | superseded | superseded_by [clm_3B0F0FD9892A](/claim/clm_3B0F0FD9892A.md) | [clm_9EA536FA1B5B](/claim/clm_9EA536FA1B5B.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000110465920087850/0001104659-20-087850-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 8,853,000,000 United States dollar | valid 2020-09-30 to 2021-03-31 | conf 0.95 | superseded | superseded_by [clm_336AC8B041A1](/claim/clm_336AC8B041A1.md) | [clm_3B0F0FD9892A](/claim/clm_3B0F0FD9892A.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000110465920121336/0001104659-20-121336-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 10,456,000,000 United States dollar | valid 2021-03-31 to 2021-06-30 | conf 0.95 | superseded | superseded_by [clm_6EAE7D00A853](/claim/clm_6EAE7D00A853.md) | [clm_336AC8B041A1](/claim/clm_336AC8B041A1.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000110465921061693/0001104659-21-061693-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 10,223,000,000 United States dollar | valid 2021-06-30 to 2021-09-30 | conf 0.95 | superseded | superseded_by [clm_D28ACE81B29C](/claim/clm_D28ACE81B29C.md) | [clm_6EAE7D00A853](/claim/clm_6EAE7D00A853.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000110465921100055/0001104659-21-100055-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 10,928,000,000 United States dollar | valid 2021-09-30 to 2022-03-31 | conf 0.95 | superseded | superseded_by [clm_8A05921A46AB](/claim/clm_8A05921A46AB.md) | [clm_D28ACE81B29C](/claim/clm_D28ACE81B29C.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000110465921133629/0001104659-21-133629-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 11,895,000,000 United States dollar | valid 2022-03-31 to 2022-06-30 | conf 0.95 | superseded | superseded_by [clm_3FFAC71D1875](/claim/clm_3FFAC71D1875.md) | [clm_8A05921A46AB](/claim/clm_8A05921A46AB.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000110465922055285/0001104659-22-055285-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 11,257,000,000 United States dollar | valid 2022-06-30 to 2022-09-30 | conf 0.95 | superseded | superseded_by [clm_1EE7A5C106ED](/claim/clm_1EE7A5C106ED.md) | [clm_3FFAC71D1875](/claim/clm_3FFAC71D1875.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000162828022020209/0001628280-22-020209-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 10,410,000,000 United States dollar | valid 2022-09-30 to 2023-03-31 | conf 0.95 | superseded | superseded_by [clm_BDD05EB44D8B](/claim/clm_BDD05EB44D8B.md) | [clm_1EE7A5C106ED](/claim/clm_1EE7A5C106ED.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000162828022027550/0001628280-22-027550-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 9,747,000,000 United States dollar | valid 2023-03-31 to 2023-06-30 | conf 0.95 | superseded | superseded_by [clm_6B2DDDB45AF4](/claim/clm_6B2DDDB45AF4.md) | [clm_BDD05EB44D8B](/claim/clm_BDD05EB44D8B.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000162828023015699/0001628280-23-015699-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 9,978,000,000 United States dollar | valid 2023-06-30 to 2023-09-30 | conf 0.95 | superseded | superseded_by [clm_3885AF18E04D](/claim/clm_3885AF18E04D.md) | [clm_6B2DDDB45AF4](/claim/clm_6B2DDDB45AF4.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000162828023027203/0001628280-23-027203-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 10,143,000,000 United States dollar | valid 2023-09-30 to 2024-03-31 | conf 0.95 | superseded | superseded_by [clm_60D18C4ED290](/claim/clm_60D18C4ED290.md) | [clm_3885AF18E04D](/claim/clm_3885AF18E04D.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000162828023035957/0001628280-23-035957-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 9,964,000,000 United States dollar | valid 2024-03-31 to 2024-06-30 | conf 0.95 | superseded | superseded_by [clm_BC21405CF5E5](/claim/clm_BC21405CF5E5.md) | [clm_60D18C4ED290](/claim/clm_60D18C4ED290.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000162828024020011/0001628280-24-020011-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 10,377,000,000 United States dollar | valid 2024-06-30 to 2024-09-30 | conf 0.95 | superseded | superseded_by [clm_12D7EF8B99CE](/claim/clm_12D7EF8B99CE.md) | [clm_BC21405CF5E5](/claim/clm_BC21405CF5E5.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000162828024033740/0001628280-24-033740-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 10,635,000,000 United States dollar | valid 2024-09-30 to 2025-03-31 | conf 0.95 | superseded | superseded_by [clm_B19E42064034](/claim/clm_B19E42064034.md) | [clm_12D7EF8B99CE](/claim/clm_12D7EF8B99CE.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000162828024044602/0001628280-24-044602-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 10,358,000,000 United States dollar | valid 2025-03-31 to 2025-06-30 | conf 0.95 | superseded | superseded_by [clm_E9EFA461ED0C](/claim/clm_E9EFA461ED0C.md) | [clm_B19E42064034](/claim/clm_B19E42064034.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000162828025021090/0001628280-25-021090-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 11,142,000,000 United States dollar | valid 2025-06-30 to 2025-09-30 | conf 0.95 | superseded | superseded_by [clm_4D4D4E6FC869](/claim/clm_4D4D4E6FC869.md) | [clm_E9EFA461ED0C](/claim/clm_E9EFA461ED0C.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000162828025036720/0001628280-25-036720-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 11,369,000,000 United States dollar | valid 2025-09-30 to 2026-03-31 | conf 0.95 | superseded | superseded_by [clm_EF0BC6C103EE](/claim/clm_EF0BC6C103EE.md) | [clm_4D4D4E6FC869](/claim/clm_4D4D4E6FC869.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000162828025047131/0001628280-25-047131-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 11,164,000,000 United States dollar | valid 2026-03-31 to 2026-06-30 | conf 0.95 | superseded | superseded_by [clm_88335AA7BB99](/claim/clm_88335AA7BB99.md) | [clm_EF0BC6C103EE](/claim/clm_EF0BC6C103EE.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000162828026028357/0001628280-26-028357-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 12,593,000,000 United States dollar | valid 2026-06-30 to 2026-09-30 | conf 0.95 | superseded | superseded_by [clm_080974839279](/claim/clm_080974839279.md) | [clm_88335AA7BB99](/claim/clm_88335AA7BB99.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/0001628280-26-050134-index.htm
- [Abbott Laboratories](/record/abbott-laboratories.md) | quarterly_revenue | 13,013,000,000 United States dollar | valid 2026-09-30 to present | conf 0.95 | valid | [clm_080974839279](/claim/clm_080974839279.md)
  sources: https://www.sec.gov/Archives/edgar/data/1800/000162828026070154/0001628280-26-070154-index.htm

## What replaced what

- $7.31 billion (2008-06-30 to 2008-09-30, [clm_53BF00022ED3](/claim/clm_53BF00022ED3.md)) was replaced by $7.5 billion from 2008-09-30 ([clm_79675DAFEFFB](/claim/clm_79675DAFEFFB.md))
- $7.5 billion (2008-09-30 to 2009-03-31, [clm_79675DAFEFFB](/claim/clm_79675DAFEFFB.md)) was replaced by $6.72 billion from 2009-03-31 ([clm_6D1B34C8DAA9](/claim/clm_6D1B34C8DAA9.md))
- $6.72 billion (2009-03-31 to 2009-06-30, [clm_6D1B34C8DAA9](/claim/clm_6D1B34C8DAA9.md)) was replaced by $7.49 billion from 2009-06-30 ([clm_3BEDCDE314E8](/claim/clm_3BEDCDE314E8.md))
- $7.49 billion (2009-06-30 to 2009-09-30, [clm_3BEDCDE314E8](/claim/clm_3BEDCDE314E8.md)) was replaced by $7.76 billion from 2009-09-30 ([clm_F40C461D1F9A](/claim/clm_F40C461D1F9A.md))
- $7.76 billion (2009-09-30 to 2010-03-31, [clm_F40C461D1F9A](/claim/clm_F40C461D1F9A.md)) was replaced by $7.7 billion from 2010-03-31 ([clm_882692ECC7C2](/claim/clm_882692ECC7C2.md))
- $7.7 billion (2010-03-31 to 2010-06-30, [clm_882692ECC7C2](/claim/clm_882692ECC7C2.md)) was replaced by $8.83 billion from 2010-06-30 ([clm_BC7C9A4BD8E1](/claim/clm_BC7C9A4BD8E1.md))
- $8.83 billion (2010-06-30 to 2010-09-30, [clm_BC7C9A4BD8E1](/claim/clm_BC7C9A4BD8E1.md)) was replaced by $8.67 billion from 2010-09-30 ([clm_A55F00358DA8](/claim/clm_A55F00358DA8.md))
- $8.67 billion (2010-09-30 to 2011-03-31, [clm_A55F00358DA8](/claim/clm_A55F00358DA8.md)) was replaced by $9.04 billion from 2011-03-31 ([clm_E6DA945AC1D9](/claim/clm_E6DA945AC1D9.md))
- $9.04 billion (2011-03-31 to 2011-06-30, [clm_E6DA945AC1D9](/claim/clm_E6DA945AC1D9.md)) was replaced by $9.62 billion from 2011-06-30 ([clm_2BC0D1181F4B](/claim/clm_2BC0D1181F4B.md))
- $9.62 billion (2011-06-30 to 2011-09-30, [clm_2BC0D1181F4B](/claim/clm_2BC0D1181F4B.md)) was replaced by $9.82 billion from 2011-09-30 ([clm_60A7CF8613BF](/claim/clm_60A7CF8613BF.md))
- $9.82 billion (2011-09-30 to 2012-03-31, [clm_60A7CF8613BF](/claim/clm_60A7CF8613BF.md)) was replaced by $9.46 billion from 2012-03-31 ([clm_D9ABEC05FB6F](/claim/clm_D9ABEC05FB6F.md))
- $9.46 billion (2012-03-31 to 2012-06-30, [clm_D9ABEC05FB6F](/claim/clm_D9ABEC05FB6F.md)) was replaced by $9.81 billion from 2012-06-30 ([clm_4F0F9A9FCDF2](/claim/clm_4F0F9A9FCDF2.md))
- $9.81 billion (2012-06-30 to 2012-09-30, [clm_4F0F9A9FCDF2](/claim/clm_4F0F9A9FCDF2.md)) was replaced by $9.77 billion from 2012-09-30 ([clm_B817BB7C1C39](/claim/clm_B817BB7C1C39.md))
- $9.77 billion (2012-09-30 to 2013-03-31, [clm_B817BB7C1C39](/claim/clm_B817BB7C1C39.md)) was replaced by $5.38 billion from 2013-03-31 ([clm_83226985F7C5](/claim/clm_83226985F7C5.md))
- $5.38 billion (2013-03-31 to 2013-06-30, [clm_83226985F7C5](/claim/clm_83226985F7C5.md)) was replaced by $5.45 billion from 2013-06-30 ([clm_A00248C0A983](/claim/clm_A00248C0A983.md))
- $5.45 billion (2013-06-30 to 2013-09-30, [clm_A00248C0A983](/claim/clm_A00248C0A983.md)) was replaced by $5.37 billion from 2013-09-30 ([clm_05BD8CC8CEE0](/claim/clm_05BD8CC8CEE0.md))
- $5.37 billion (2013-09-30 to 2014-03-31, [clm_05BD8CC8CEE0](/claim/clm_05BD8CC8CEE0.md)) was replaced by $5.24 billion from 2014-03-31 ([clm_B233A6055639](/claim/clm_B233A6055639.md))
- $5.24 billion (2014-03-31 to 2014-06-30, [clm_B233A6055639](/claim/clm_B233A6055639.md)) was replaced by $5.55 billion from 2014-06-30 ([clm_FD8317313DF1](/claim/clm_FD8317313DF1.md))
- $5.55 billion (2014-06-30 to 2014-09-30, [clm_FD8317313DF1](/claim/clm_FD8317313DF1.md)) was replaced by $5.1 billion from 2014-09-30 ([clm_82A6A707FD7C](/claim/clm_82A6A707FD7C.md))
- $5.1 billion (2014-09-30 to 2015-03-31, [clm_82A6A707FD7C](/claim/clm_82A6A707FD7C.md)) was replaced by $4.9 billion from 2015-03-31 ([clm_217D209218A4](/claim/clm_217D209218A4.md))
- $4.9 billion (2015-03-31 to 2015-06-30, [clm_217D209218A4](/claim/clm_217D209218A4.md)) was replaced by $5.17 billion from 2015-06-30 ([clm_1E113FF89F7B](/claim/clm_1E113FF89F7B.md))
- $5.17 billion (2015-06-30 to 2015-09-30, [clm_1E113FF89F7B](/claim/clm_1E113FF89F7B.md)) was replaced by $5.15 billion from 2015-09-30 ([clm_4DDA3D71417E](/claim/clm_4DDA3D71417E.md))
- $5.15 billion (2015-09-30 to 2016-03-31, [clm_4DDA3D71417E](/claim/clm_4DDA3D71417E.md)) was replaced by $4.89 billion from 2016-03-31 ([clm_33CB344232AF](/claim/clm_33CB344232AF.md))
- $4.89 billion (2016-03-31 to 2016-06-30, [clm_33CB344232AF](/claim/clm_33CB344232AF.md)) was replaced by $5.33 billion from 2016-06-30 ([clm_1B83117F5484](/claim/clm_1B83117F5484.md))
- $5.33 billion (2016-06-30 to 2016-09-30, [clm_1B83117F5484](/claim/clm_1B83117F5484.md)) was replaced by $5.3 billion from 2016-09-30 ([clm_8064646C7C6E](/claim/clm_8064646C7C6E.md))
- $5.3 billion (2016-09-30 to 2017-03-31, [clm_8064646C7C6E](/claim/clm_8064646C7C6E.md)) was replaced by $6.34 billion from 2017-03-31 ([clm_15BAEA02B893](/claim/clm_15BAEA02B893.md))
- $6.34 billion (2017-03-31 to 2017-06-30, [clm_15BAEA02B893](/claim/clm_15BAEA02B893.md)) was replaced by $6.64 billion from 2017-06-30 ([clm_29C8A48CFFA6](/claim/clm_29C8A48CFFA6.md))
- $6.64 billion (2017-06-30 to 2017-09-30, [clm_29C8A48CFFA6](/claim/clm_29C8A48CFFA6.md)) was replaced by $6.83 billion from 2017-09-30 ([clm_402A58FFA584](/claim/clm_402A58FFA584.md))
- $6.83 billion (2017-09-30 to 2018-03-31, [clm_402A58FFA584](/claim/clm_402A58FFA584.md)) was replaced by $7.39 billion from 2018-03-31 ([clm_C3C0F612B29F](/claim/clm_C3C0F612B29F.md))
- $7.39 billion (2018-03-31 to 2018-06-30, [clm_C3C0F612B29F](/claim/clm_C3C0F612B29F.md)) was replaced by $7.77 billion from 2018-06-30 ([clm_79374FAAB118](/claim/clm_79374FAAB118.md))
- $7.77 billion (2018-06-30 to 2018-09-30, [clm_79374FAAB118](/claim/clm_79374FAAB118.md)) was replaced by $7.66 billion from 2018-09-30 ([clm_DE1BAF682D4F](/claim/clm_DE1BAF682D4F.md))
- $7.66 billion (2018-09-30 to 2019-03-31, [clm_DE1BAF682D4F](/claim/clm_DE1BAF682D4F.md)) was replaced by $7.54 billion from 2019-03-31 ([clm_C0322CACEF5F](/claim/clm_C0322CACEF5F.md))
- $7.54 billion (2019-03-31 to 2019-06-30, [clm_C0322CACEF5F](/claim/clm_C0322CACEF5F.md)) was replaced by $7.98 billion from 2019-06-30 ([clm_BDDE4A079F3F](/claim/clm_BDDE4A079F3F.md))
- $7.98 billion (2019-06-30 to 2019-09-30, [clm_BDDE4A079F3F](/claim/clm_BDDE4A079F3F.md)) was replaced by $8.08 billion from 2019-09-30 ([clm_6EA4DA762D97](/claim/clm_6EA4DA762D97.md))
- $8.08 billion (2019-09-30 to 2020-03-31, [clm_6EA4DA762D97](/claim/clm_6EA4DA762D97.md)) was replaced by $7.73 billion from 2020-03-31 ([clm_0C0541A5EB25](/claim/clm_0C0541A5EB25.md))
- $7.73 billion (2020-03-31 to 2020-06-30, [clm_0C0541A5EB25](/claim/clm_0C0541A5EB25.md)) was replaced by $7.33 billion from 2020-06-30 ([clm_9EA536FA1B5B](/claim/clm_9EA536FA1B5B.md))
- $7.33 billion (2020-06-30 to 2020-09-30, [clm_9EA536FA1B5B](/claim/clm_9EA536FA1B5B.md)) was replaced by $8.85 billion from 2020-09-30 ([clm_3B0F0FD9892A](/claim/clm_3B0F0FD9892A.md))
- $8.85 billion (2020-09-30 to 2021-03-31, [clm_3B0F0FD9892A](/claim/clm_3B0F0FD9892A.md)) was replaced by $10.46 billion from 2021-03-31 ([clm_336AC8B041A1](/claim/clm_336AC8B041A1.md))
- $10.46 billion (2021-03-31 to 2021-06-30, [clm_336AC8B041A1](/claim/clm_336AC8B041A1.md)) was replaced by $10.22 billion from 2021-06-30 ([clm_6EAE7D00A853](/claim/clm_6EAE7D00A853.md))
- $10.22 billion (2021-06-30 to 2021-09-30, [clm_6EAE7D00A853](/claim/clm_6EAE7D00A853.md)) was replaced by $10.93 billion from 2021-09-30 ([clm_D28ACE81B29C](/claim/clm_D28ACE81B29C.md))
- $10.93 billion (2021-09-30 to 2022-03-31, [clm_D28ACE81B29C](/claim/clm_D28ACE81B29C.md)) was replaced by $11.9 billion from 2022-03-31 ([clm_8A05921A46AB](/claim/clm_8A05921A46AB.md))
- $11.9 billion (2022-03-31 to 2022-06-30, [clm_8A05921A46AB](/claim/clm_8A05921A46AB.md)) was replaced by $11.26 billion from 2022-06-30 ([clm_3FFAC71D1875](/claim/clm_3FFAC71D1875.md))
- $11.26 billion (2022-06-30 to 2022-09-30, [clm_3FFAC71D1875](/claim/clm_3FFAC71D1875.md)) was replaced by $10.41 billion from 2022-09-30 ([clm_1EE7A5C106ED](/claim/clm_1EE7A5C106ED.md))
- $10.41 billion (2022-09-30 to 2023-03-31, [clm_1EE7A5C106ED](/claim/clm_1EE7A5C106ED.md)) was replaced by $9.75 billion from 2023-03-31 ([clm_BDD05EB44D8B](/claim/clm_BDD05EB44D8B.md))
- $9.75 billion (2023-03-31 to 2023-06-30, [clm_BDD05EB44D8B](/claim/clm_BDD05EB44D8B.md)) was replaced by $9.98 billion from 2023-06-30 ([clm_6B2DDDB45AF4](/claim/clm_6B2DDDB45AF4.md))
- $9.98 billion (2023-06-30 to 2023-09-30, [clm_6B2DDDB45AF4](/claim/clm_6B2DDDB45AF4.md)) was replaced by $10.14 billion from 2023-09-30 ([clm_3885AF18E04D](/claim/clm_3885AF18E04D.md))
- $10.14 billion (2023-09-30 to 2024-03-31, [clm_3885AF18E04D](/claim/clm_3885AF18E04D.md)) was replaced by $9.96 billion from 2024-03-31 ([clm_60D18C4ED290](/claim/clm_60D18C4ED290.md))
- $9.96 billion (2024-03-31 to 2024-06-30, [clm_60D18C4ED290](/claim/clm_60D18C4ED290.md)) was replaced by $10.38 billion from 2024-06-30 ([clm_BC21405CF5E5](/claim/clm_BC21405CF5E5.md))
- $10.38 billion (2024-06-30 to 2024-09-30, [clm_BC21405CF5E5](/claim/clm_BC21405CF5E5.md)) was replaced by $10.64 billion from 2024-09-30 ([clm_12D7EF8B99CE](/claim/clm_12D7EF8B99CE.md))
- $10.64 billion (2024-09-30 to 2025-03-31, [clm_12D7EF8B99CE](/claim/clm_12D7EF8B99CE.md)) was replaced by $10.36 billion from 2025-03-31 ([clm_B19E42064034](/claim/clm_B19E42064034.md))
- $10.36 billion (2025-03-31 to 2025-06-30, [clm_B19E42064034](/claim/clm_B19E42064034.md)) was replaced by $11.14 billion from 2025-06-30 ([clm_E9EFA461ED0C](/claim/clm_E9EFA461ED0C.md))
- $11.14 billion (2025-06-30 to 2025-09-30, [clm_E9EFA461ED0C](/claim/clm_E9EFA461ED0C.md)) was replaced by $11.37 billion from 2025-09-30 ([clm_4D4D4E6FC869](/claim/clm_4D4D4E6FC869.md))
- $11.37 billion (2025-09-30 to 2026-03-31, [clm_4D4D4E6FC869](/claim/clm_4D4D4E6FC869.md)) was replaced by $11.16 billion from 2026-03-31 ([clm_EF0BC6C103EE](/claim/clm_EF0BC6C103EE.md))
- $11.16 billion (2026-03-31 to 2026-06-30, [clm_EF0BC6C103EE](/claim/clm_EF0BC6C103EE.md)) was replaced by $12.59 billion from 2026-06-30 ([clm_88335AA7BB99](/claim/clm_88335AA7BB99.md))
- $12.59 billion (2026-06-30 to 2026-09-30, [clm_88335AA7BB99](/claim/clm_88335AA7BB99.md)) was replaced by $13.01 billion from 2026-09-30 ([clm_080974839279](/claim/clm_080974839279.md))

## Questions this record answers

### What is Abbott Laboratories's current quarterly revenue?

$13.01 billion, dated September 30, 2026, from a primary source (sec.gov). The record asserts this claim as of November 9, 2026 (status valid, confidence 0.95).

### When did Abbott Laboratories's quarterly revenue last change?

The latest value on the record is $13.01 billion, dated September 30, 2026; before it the record holds $12.59 billion, dated June 30, 2026 and closed on September 30, 2026.

### What was Abbott Laboratories's quarterly revenue before $13.01 billion?

$12.59 billion, valid from June 30, 2026 to September 30, 2026 (status superseded), from a primary source (sec.gov).


## Read on

- This page: /record/abbott-laboratories/quarterly_revenue (markdown: /record/abbott-laboratories/quarterly_revenue.md)
- Entity twin: /record/abbott-laboratories.md · timeline: /timelines/abbott-laboratories.md
- Every company's quarterly revenue: /facts/quarterly_revenue.md

---

AsOf is a temporal fact ledger: a structured, dated, sourced record of what is true and what changed, built for AI retrieval.